



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

July 21, 2023

Nicole LaBrosse
Senior Vice President and Chief Financial Officer
Halozyme Therapeutics, Inc.
12390 El Camino Real
San Diego, CA 92130

Re: Halozyme Therapeutics, Inc
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed February 21, 2023
File No. 001-32335

Dear Nicole LaBrosse:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences